Media coverage about Phibro Animal Health (NASDAQ:PAHC) has trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Phibro Animal Health earned a news impact score of 0.17 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.7961809105586 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Phibro Animal Health (NASDAQ PAHC) opened at $33.50 on Monday. The company has a market capitalization of $1,346.13, a P/E ratio of 19.71, a PEG ratio of 3.93 and a beta of 1.27. Phibro Animal Health has a one year low of $26.10 and a one year high of $40.25. The company has a debt-to-equity ratio of 1.91, a current ratio of 3.26 and a quick ratio of 1.85.
Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Monday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.37 by $0.01. The business had revenue of $193.40 million during the quarter, compared to analysts’ expectations of $189.89 million. Phibro Animal Health had a return on equity of 42.75% and a net margin of 8.87%. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.36 earnings per share. analysts expect that Phibro Animal Health will post 1.57 earnings per share for the current year.
A number of research analysts have recently commented on PAHC shares. BidaskClub cut Phibro Animal Health from a “hold” rating to a “sell” rating in a research note on Saturday, December 2nd. Piper Jaffray Companies set a $41.00 target price on Phibro Animal Health and gave the company a “buy” rating in a research note on Friday, October 6th. ValuEngine cut Phibro Animal Health from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Finally, Zacks Investment Research cut Phibro Animal Health from a “hold” rating to a “sell” rating in a research note on Wednesday, November 8th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $38.25.
COPYRIGHT VIOLATION WARNING: This piece was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2018/01/01/phibro-animal-health-pahc-given-coverage-optimism-rating-of-0-17.html.
About Phibro Animal Health
Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.